Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.

Autor: Krug S; Department of Internal Medicine I, Martin Luther University Halle/Wittenberg, Halle (Saale), Germany.; Department of Gastroenterology and Endocrinology, Philipps-University, Marburg, Germany., Mordhorst JP; Department of Internal Medicine I, Martin Luther University Halle/Wittenberg, Halle (Saale), Germany., Moser F; Department of Internal Medicine I, Martin Luther University Halle/Wittenberg, Halle (Saale), Germany., Theuerkorn K; Department of Internal Medicine I, Martin Luther University Halle/Wittenberg, Halle (Saale), Germany., Ruffert C; Department of Internal Medicine I, Martin Luther University Halle/Wittenberg, Halle (Saale), Germany., Egidi M; Department of Internal Medicine I, Martin Luther University Halle/Wittenberg, Halle (Saale), Germany., Rinke A; Department of Gastroenterology and Endocrinology, Philipps-University, Marburg, Germany., Gress TM; Department of Gastroenterology and Endocrinology, Philipps-University, Marburg, Germany., Michl P; Department of Internal Medicine I, Martin Luther University Halle/Wittenberg, Halle (Saale), Germany.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2019 Jun 25; Vol. 14 (6), pp. e0218953. Date of Electronic Publication: 2019 Jun 25 (Print Publication: 2019).
DOI: 10.1371/journal.pone.0218953
Abstrakt: Somatostatin analogues (SSA) represent the standard of care for symptom control in patients with functional gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). In addition, SSA exert significant anti-proliferative effects in mid-gut and pancreatic NET (PanNET). In parallel, molecularly targeted therapies (MTT) have been shown to improve progression free survival (PFS) in patients with PanNET. However, due to either primary or acquired resistance to MTT, their impact on overall survival (OS) remains unclear. To date, various hypotheses exist to explain differences in patient responsiveness to SSA and MTT. However, data addressing one of the most pivotal questions, whether combining SSA with novel MTT will result in synergistic or additive efficacy compared to monotherapy, are lacking. The aim of this study is to characterize the interaction, optimal sequence and dosing of SSA-based and molecularly targeted therapies in PanNET. Somatostatin receptor subtypes 1-5 (SSTR) were evaluated in the neuroendocrine cell lines Bon1, QGP1 and Ins-1 via immunoblot and qRT-PCR. The impact of the SSA-analogue lanreotide alone or in combination with the MTT sunitinib, everolimus and regorafenib on intracellular signalling, hormone secretion and cell proliferation was determined in cell lysates and supernatants. In addition, synergistic effects of SSA and MTT in various sequential therapeutic approaches were investigated. SSTR were differently expressed in the examined neuroendocrine tumor cell lines. SSTR modulation via lanreotide moderately influenced proliferation, mainly via modulating AKT and ERK signalling, which was paralleled by decreased chromogranin A (CgA) expression and secretion. Interestingly, MTT treatment with regorafenib upregulated the expression of SSTR-2 and -5, while sunitinib and everolimus did not significantly alter SSTR expression. Cell viability was significantly reduced by all MTT, with regorafenib exerting the most significant effects. However, compared to the marked effects of MTT alone, synergistic effects of combined MTT and lanreotide treatment were only modest and time- and dose-dependent. SSTR are differentially expressed in various NEN cell lines. Their expression is influenced by MTT treatment. Various sequential or simultaneous combinations of lanreotide and MTT did not lead to significant synergistic effects.
Competing Interests: Ipsen Inc. acted as commercial funder, however, no other relevant declarations are present. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje